These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 26270229

  • 1. Parathyroid Hormone Plus Alendronate in Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
    Wang C, Zhang G, Gu M, Fan J, Chen J, Zhang G, Li B.
    J Invest Surg; 2015; 28(6):309-16. PubMed ID: 26270229
    [Abstract] [Full Text] [Related]

  • 2. Parathyroid hormone plus alendronate in osteoporosis: a meta-analysis of randomized controlled trials.
    Zhang Q, Qian J, Zhu Y.
    Int J Clin Exp Med; 2015; 8(3):3338-48. PubMed ID: 26064224
    [Abstract] [Full Text] [Related]

  • 3. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
    Shen L, Xie X, Su Y, Luo C, Zhang C, Zeng B.
    PLoS One; 2011; 6(10):e26267. PubMed ID: 22022584
    [Abstract] [Full Text] [Related]

  • 4. Alendronate for the Treatment of Osteoporosis in Men: A Meta-Analysis of Randomized Controlled Trials.
    Xu Z.
    Am J Ther; 2017; 24(2):e130-e138. PubMed ID: 27058577
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.
    Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P.
    Osteoporos Int; 2007 Jan; 18(1):45-57. PubMed ID: 16951908
    [Abstract] [Full Text] [Related]

  • 8. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM.
    N Engl J Med; 2003 Sep 25; 349(13):1216-26. PubMed ID: 14500805
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
    Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP.
    J Clin Endocrinol Metab; 2011 Aug 25; 96(8):2441-9. PubMed ID: 21593114
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul 25; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.